It's still a science-driven company.

Its TipRanks
Its wkly rrgchart
Its StockCharts GalleryView

Komen:

notes from BoA Global Research: "Over the last twelve months, DD shares have outperformed the S&P500 Chemical Index by 14.1% and the broader S&P500 by 20.5%. Outperformance since 1 Oct. 2020, when we believe arbitrage investors began buying shares to participate in the Nutrition & Biosciences (N&B) sale to IFF, has been an even more impressive 34.8% and 40.7%, respectively. Shares have responded well to resilient demand in electronics, resurgent strength in auto sales, an improving price backdrop in nylon polymers, and, as we will discuss below, a significant tailwind from deal-related buying. Indeed, we think the company is set up for a strong earnings performance in 2021 and see a favorable pro forma leverage profile that will provide further flexibility to drive growth. However, with shares now trading near 14x pro forma EBITDA, and carrying just over 2% upside to our new $86 PO, we are inclined to step back on our Buy rating as valuation is closer to fair.

Komen:

Technical tailwinds shift to headwinds as tender closes

Komen:

Headline risk to PFOA may pick up on Blue Wave

Komen:

The company now operates through three primary reporting segments: Electronics & Imaging, Transportation & Industrial Polymers, and Safety & Construction. These businesses are allocated based on process technology, product application, and end market exposures.

Komen:

its weekly chart after its earning report.